Teva
Biosimilar developer, Israel. 4 development products across 4 molecules: denosumab, filgrastim, follitropin alfa, ranibizumab.
First approval in the Atlas: Sep 2008, Ratiograstim, filgrastim (EMA)
FDAproducts approved1
EMAproducts approved3
PMDAproducts approved0
HCproducts approved1
CDSCOproducts approved0
EDEproducts registered1
Portfolio by market
| Molecule | Product | FDA | EMA | PMDA | HC | CDSCO | EDE |
|---|---|---|---|---|---|---|---|
| Denosumab | Ponlimsi / Degevma TVB-009 | Mar 2026 | Nov 2025 | · | · | · | · |
| Filgrastim | Tevagrastim / Ratiograstim XM02 | · | Sep 2008 | · | · | · | Jun 2022 |
| Follitropin alfa | Ovaleap XM17 | · | Sep 2013 | · | · | · | · |
| Ranibizumab | Ranopto | · | · | · | Oct 2023 | · | · |
Month shown is the first approval or registration of that product in that market.
Chronology
- EMASep 2008Ratiograstim, filgrastim
- EMASep 2008Tevagrastim, filgrastim
- EMASep 2013Ovaleap, follitropin alfa
- EDEJun 2022TevaGrastim, filgrastim
- HCOct 2023Ranopto, ranibizumab
- EMANov 2025Degevma, denosumab
- EMANov 2025Ponlimsi, denosumab
- FDAMar 2026Ponlimsi, denosumab
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.